Lampalizumab
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | CFD |
| Clinical data | |
| Routes of administration | Intravitreal |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2068H3214N546O676S13 |
| Molar mass | 46958.39 g·mol−1 |
Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.[1][2]
One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point.[3] The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.[4]
These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.[5]
References
[edit]- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab" (PDF). American Medical Association.
- ^ "Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration". www.roche.com. Retrieved 2017-09-14.
- ^ "Statement on Chroma Study". www.roche.com. Retrieved 2017-11-10.
- ^ Dolgin E (November 2017). "Age-related macular degeneration foils drugmakers". Nature Biotechnology. 35 (11): 1000–1001. doi:10.1038/nbt1117-1000. PMID 29121027. S2CID 9682962.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |